Business
Tyra Biosciences to Present at the 2021 Jefferies London Healthcare Conference
CARLSBAD, Calif., Nov. 10, 2021 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built
About this update from Tyra Biosciences, Inc.
[{"type":"text","content":"CARLSBAD, Calif., Nov. 10, 2021 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that TYRA management will participate in a fireside chat and host one-on-one investor meetings during the virtual portion of the 2021 Jefferies London Healthcare Conference, taking place November 18-November 19, 2021. The fireside chat will be available on-demand for attendees during the virtual conference beginning on Thursday, November 18, 2021.\nA webcast of the fireside chat will be available on the Company's website at https://tyra.bio in the \"For Investors\" section following conclusion of the conference. \nAbout Tyra Biosciences\nTyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. TYRA is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. TYRA is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. TYRA is advancing multiple product candidates toward the clinic including its lead product candidate TYRA-300, an FGFR3 inhibitor with an initial focus on patients with bladder cancer, and TYRA-200, an FGFR2 inhibitor with an initial focus on patients with intrahepatic cholangiocarcinoma who have developed drug resistance mutations from existing FGFR inhibitors. \nForward-Looking Statements\nThis news release contains \"forward-looking statements\" as defined by the Private Securities Litigation Reform Act of 1995. TYRA cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. TYRA undertakes no obligation to update or revise any forward-looking statements. For a further descri...